- Blood gas testing is often required for ventilatory-assisted patients and those undergoing evaluation for respiratory distress, providing insights into a patient’s oxygenation level.
- The new RAPIDPoint 500e Blood Gas Analyzer incorporates Integri-sense Technology to deliver accurate test results at the point of care.
- Robust data security features, hands-free automatic sampling, and one-touch operation streamline workflow and functionality to maximize clinician focus on patient care.
Siemens Healthineers announced today that its latest critical care testing solution, the RAPIDPoint® 500e Blood Gas Analyzer, has been licensed for sale by Health Canada. The analyzer generates blood gas, electrolyte, metabolite, CO-oximetry, and neonatal bilirubin results, which are used to diagnose and monitor critically ill patients in the intensive care unit, operating room, or emergency room.
“Monitoring respiratory conditions in critical care settings is key for Point-of-care teams that need a blood gas testing solution that delivers fast, accurate results and increases workflow efficiencies,” said Ingrid Lansard, Head of Point of Care, Siemens Healthineers Canada. “With cybersecurity an increasing concern in healthcare settings, having a safe operating environment is paramount, and the RAPIDPoint 500e Blood Gas Analyzer is equipped with MacAfee embedded anti-malware, two-step authentication process, encrypted password requirements for patient data transfer, and firewall inclusion to block potential hacking attempts.”
The RAPIDPoint 500e Blood Gas Analyzer is an essential instrument supporting COVID-19 response efforts, where blood gas testing plays a critical role in managing infected patients and monitoring their respiratory distress. Routine blood gas testing is also performed when
patients require mechanical ventilation. Arterial blood gas tests provide the status of a patient’s oxygenation levels and enable healthcare providers to determine whether adjustments to ventilator settings or other treatments are required.
The analyzer elevates confidence in patient results with Integri-sense™ Technology, a comprehensive series of automated functional checks designed to deliver accurate test results at the point-of-care.
“Integri-sense technology provides frequent quality and blood integrity checks before, during, and after every patient sample,” said Sarah Gamble, Business Manager, Point of Care, Siemens Healthineers Canada. “This technology also provides three levels of independent automatic quality control, multiple calibration routines, and advanced software algorithms, making for reliable and clinically actionable test results each and every time.”
Additionally, the RAPIDPoint 500e Blood Gas Analyzer integrates seamlessly into hospital networks with the Siemens Healthineers Point of Care Ecosystem™, which offers convenient, remote management of operators and devices located across multiple sites.
“In all, this system is designed to allow the healthcare practitioner to focus on their patients thanks to its maintenance-free features, user-friendly interface, and simplified workflows,” continued Ingrid Lansard. “It’s simplicity doesn’t stop there: the syringe and capillary samples are handled in the same manner with automated hands-free sampling to eliminate operator variability, and the analyzer also boasts a advanced clot management and air bubble detection mechanism, as well as providing for low sample volumes.”
For more information about the RAPIDPoint 500e Blood Gas Analyzer, visit https://www.siemens-healthineers.com/en-ca/blood-gas/blood-gas-systems/rapidpoint-500e-systems
Contact for journalists
Alastair Harris-Cartwright
Phone: +1 905-399-8491; E-mail: alastair.harris-cartwright@siemens-healthineers.com
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion. Further information is available at www.siemens-healthineers.com.